

Disulphide-less crotonamine is effective for formation of DNA–peptide complex but is unable to improve bovine embryo transfection

Research Article

Cite this article: Freitas VJF *et al.* (2020) Disulphide-less crotonamine is effective for formation of DNA–peptide complex but is unable to improve bovine embryo transfection. *Zygote* 28: 72–79. doi: [10.1017/S0967199419000716](https://doi.org/10.1017/S0967199419000716)


Received: 24 February 2019
Revised: 3 September 2019
Accepted: 7 October 2019
First published online: 30 October 2019

Keywords:

Embryotoxicity; Gene delivery; Microinjection; Nucleic acid–peptide complex; Transgenesis

Authors for correspondence:

Vicente J.F. Freitas. State University of Ceará, Av. Dr. Silas Mungusba, 1700 – Fortaleza, CE 60714-903, Brazil. Tel: +55 85 3101 9861. E-mail: vicente.freitas@uece.br; Gandhi Rádis-Baptista. Federal University of Ceará, Av. da Abolição, 3207 – Fortaleza – CE 60165-081, Brazil. Tel: +55 85 3366 7000, E-mail: radisbra@yahoo.com

Vicente J.F. Freitas¹ , Iana S. Campelo¹, Mirelly M.A.S. Silva¹, Camila M. Cavalcanti¹, Dárcio I.A. Teixeira¹, Luiz S.A. Camargo², Luciana M. Melo^{1,3} and Gandhi Rádis-Baptista⁴

¹Laboratory of Physiology and Control of Reproduction, Faculty of Veterinary, State University of Ceará (UECE), Fortaleza, Brazil; ²Embrapa Dairy Cattle, Juiz de Fora, Brazil; ³Molecular Genetics Research Unit, University Center Fametro (UNIFAMETRO), Fortaleza, Brazil and ⁴Laboratory of Biochemistry and Biotechnology, Institute of Marine Science, Federal University of Ceará (UFC), Fortaleza, Brazil

Summary

This study aimed to investigate the ability of disulphide-less crotonamine (dLCr) to complex DNA and to evaluate whether the DNA–dLCr complex is capable of improving transfection in bovine embryos. Three experiments were performed to: (i) evaluate the formation and stability of the DNA–dLCr complex; (ii) assess the dLCr embryotoxicity by exposure of bovine embryos to dLCr; and (iii) assess the efficiency of bovine embryo transfection after microinjection of the DNA–dLCr complex or green fluorescent protein (GFP) plasmid alone (control). DNA complexation by dLCr after 30 min of incubation at 1:100 and 1:50 proportions presented higher efficiency ($P < 0.05$) than the two controls: native crotonamine (NCr) 1:10 and lipofectamine. There was no difference between DNA–dLCr 1:25 and the controls. The DNA–dLCr complexation was evaluated at different proportions and times. In all, at least half of maximum complexation was achieved within the initial 30 min. No embryotoxicity of dLCr was verified after exposure of *in vitro* fertilized embryos to different concentrations of the peptide. The effectiveness of dLCr to improve exogenous gene expression was evaluated by microinjection of the DNA–dLCr complex into *in vitro* fertilized zygotes, followed by verification of both embryo development and GFP expression. From embryos microinjected with DNA only, 4.6% and 2.8% expressed the GFP transgene at day 5 and day 7, respectively. The DNA–dLCr complex did not increase the number of GFP-positive embryos. In conclusion, dLCr forms a complex with DNA and its application in *in vitro* culture is possible. However, the dLCr peptide sequence should be redesigned to improve GFP expression.

Introduction

Transgenic technology in animals has been extensively used for many purposes. The use of the traditional methods to obtain transgenic mammals dates back to the 1970s (Jaenisch and Mintz, 1974) and led to the production of the first transgenic mice by pronuclear microinjection (Gordon *et al.*, 1980). Later, transgenic animals were produced from different species such as rabbit, sheep, pig (Hammer and Pursel, 1985), cattle (Krimpenfort *et al.*, 1991) and goat (Ebert *et al.*, 1991). However, this technique presents several drawbacks, ranging from low transfection efficiency to high cost of equipment and the need for skilled personal (Kues and Niemann, 2011). To overcome these disadvantages several strategies have been developed such as sperm-mediated gene transfer (Chang *et al.*, 2002), gene transfer mediated by cationic lipids (Carballada *et al.*, 2002), transfection of donor cells followed by nuclear transfer (Salamone *et al.*, 2006), gene transfer mediated by retroviruses (Xu *et al.*, 2013) and, more recently, genome editing using the CRISPR/Cas9 system (Li *et al.*, 2018).

For continuous improvement of transgenic technology, it is necessary to develop simple, affordable and efficient methods. Therefore, in recent decades, studies concerning the use of cell-penetrating peptides (CPPs) in transgenesis have been investigated (Rádis-Baptista *et al.*, 2017). CPPs are represented by short cationic or amphipathic oligopeptides that translocate across the plasma membrane and penetrate eukaryotic cells (Pooga and Langel, 2015). These peptides can usually carry different categories of therapeutic substances into the cells, including pharmaceuticals, fluorescent probes, proteins, DNA and RNA (Stewart *et al.*, 2008).

A few years ago, our group started studies with crotonamine, one of these CPPs, for potential use in animal transgenesis (Campelo *et al.*, 2016a, 2016b), exploring its ability to stable binding to nucleic acids by electrostatic interaction and forming DNA–peptide complex. Crotonamine was first reported back in 1947 as one of the predominant components in the venom of South

American rattlesnake *Crotalus durissus terrificus* (Gonçalves and Polson, 1947). More recently, crodamine was described as a novel CPP capable of translocation and be located in the cytoplasm of different eukaryotic cells (Kerkis *et al.*, 2004; Nascimento *et al.*, 2007) and preimplantation embryos such as mouse morulas (Kerkis *et al.*, 2004) and bovine zygotes (Campelo *et al.*, 2016a). It was also demonstrated that this venom-derived peptide is able to successfully transfect cells in murine model (Nascimento *et al.*, 2007). However, when using bovine as a model for gene delivery, crodamine did not improve gene transfer possibly due to its high affinity for DNA molecules (Campelo *et al.*, 2016b).

Therefore, crodamine structural derivatives and analogues have been designed and investigated for their efficiency of cell penetration and delivery of molecules. In this scenario, short crodamine-derived peptides (named NrTPs) have been evaluated for cellular uptake and retained some desirable properties of crodamine such as efficient cell uptake, nuclear homing and cellular labelling. Noteworthy, other advantageous properties (short size, nucleolar targeting, facility for zip-code localization of therapeutic protein) were improved in comparison with the native peptide (Rádis-Baptista *et al.*, 2008; Rádis-Baptista *et al.*, 2012). Therefore, the aim of the present study was to investigate the feasibility of using another variation of crodamine structure, i.e. a disulphide-less (linear) crodamine (dLCr) that could deliver nucleic acids (genes) and facilitate the DNA-peptide intracellular dissociation, aimed at the transfection of bovine embryos. With such purpose, the present work evaluated: (i) the ability of dLCr to form complex, under several *in vitro* conditions, with a plasmid harbouring the reporter gene for green fluorescent protein (GFP); (ii) the toxicity of dLCr toward *in vitro* fertilized (IVF) bovine embryos; and (iii) the effectiveness of dLCr to improve the expression of GFP transgene in embryos derived from *in vitro* fertilized bovine zygotes injected with DNA-dLCr.

Material and methods

Experimental design

This study consisted of three different experiments. In experiment 1, DNA-dLCr complex formation and stability were initially evaluated under different *in vitro* conditions to establish the parameters for further embryo transfection. In experiment 2, dLCr embryo toxicity was assessed by exposure of bovine embryos to dLCr. Finally, in experiment 3, expression of the GFP reporter gene was used to assess the efficiency of bovine embryo transfection after microinjection of the DNA-dLCr complex or GFP plasmid alone (control).

Disulphide-less and native versions of crodamine

Native crodamine (NcR) was purified from the crude venom of rattlesnakes kept in the serpentarium of São Paulo University (Ribeirão Preto, Brazil). The method for NcR preparation was as described previously (Kerkis *et al.*, 2004). dLCr was prepared commercially by solid peptide synthesis (China Peptides Co., Shanghai, China) using the designed sequence C-YKQSHKKGGHAbuFPKEKIAbuLPPSSDFGKMDAbuRWRWKAAbuAbuK-KGSG (MW 4886.73). This new version of crodamine structure does not form intrachain or interchain disulphide bonds due to the replacement of cysteine residues for 2-aminobutyric acid (Abu). Lyophilized dLCr was stored at -20°C until use.

Plasmid DNA preparation

The circular plasmid pEGFP-N1 (Clontech Laboratories Inc., Mountain View, CA, USA), comprised of a reporter gene encoding GFP driven by the cytomegalovirus (CMV) promoter (GenBank accession no. U55762) was used. The plasmid was cloned and propagated in *Escherichia coli* and purified using the PureLink™ Quick Plasmid Miniprep Kit (Invitrogen Co., Carlsbad, CA, USA) according to the manufacturer's instructions.

Experiment 1: Conditions of DNA-dLCr complex formation

Stoichiometry and kinetics of complex formation

To determine the stoichiometry of DNA-dLCr complex, a fixed concentration of pEGFP-N1 (25 ng/ μl) was combined with increasing concentrations of dLCr (0.25, 0.625, 1.25 or 2.5 $\mu\text{g}/\mu\text{l}$) resulting in DNA:peptide mass ratios of 1:10, 1:25, 1:50 and 1:100, respectively. Both DNA-NcR complex and DNA-lipofectamine lipoplex were positive controls. A DNA-NcR complex was formed by mixing pEGFP-N1 at 25 ng/ μl with NcR at 0.25 $\mu\text{g}/\mu\text{l}$ (1:10; DNA:peptide; wt:wt). The lipoplex was prepared using Lipofectamine 2000 Reagent (Invitrogen Co.) and pEGFP-N1 as indicated by the manufacturer. All complex formations were measured after 30 min of incubation. In another assay, the kinetics of complex formation was monitored at 0, 5, 30, 60 and 90 min. DNA-peptides complexes were prepared as described above to achieve DNA:peptide mass ratios of 1:10, 1:25 and 1:50 for DNA-dLCr, and 1:10 for the DNA-NcR (positive control). For both assays, the complexes were prepared in 150 mM NaCl solution at approximately 26°C . The percentage of complexed DNA was measured indirectly using an 'in-lab' developed methodology based on the fluorophore exclusion assay and the Qubit dsDNA High Sensitivity (HS) Assay Kit (Life Technologies, Eugene, OR, USA), using a Qubit 2.0 fluorimeter (Invitrogen Co.) for readings, as previously described (Freitas *et al.*, 2014). Negative controls were prepared using DNA at the same concentrations described previously in the absence of peptide and were used for fluorescence signal normalization. Each assay was repeated three times and groups were performed in duplicate within repetitions.

Complex stability in embryo culture medium

The stability of the DNA-dLCr complex was evaluated in synthetic oviductal fluid (SOF) medium in the absence of fetal calf serum, albumin and amino acids (SOF^{-saa}). Therefore, the DNA-dLCr complex was previously prepared by 30 min incubation of dLCr mixed with pEGFP-N1 at a DNA:peptide mass ratio of 1:25 (the best condition defined in the kinetics assay). Samples were recovered at 0, 180 and 360 min after DNA-dLCr dilution in SOF^{-saa} medium (1:10; v:v) to measure the fluorescence signal. The concentration of complexed DNA was evaluated using the Qubit dsDNA HS Assay Kit and a Qubit 2.0 fluorimeter as previously. NcR was used as the positive control at a 1:10 DNA:peptide mass ratio as described before. The experimental groups were performed in duplicate in each repetition and the assay was repeated three times.

Experiment 2: Evaluation of dLCr embryotoxicity

Oocyte collection and *in vitro* maturation (IVM)

Bovine ovaries were collected from a local slaughterhouse and transported on ice to the laboratory in 0.9% (w:v) NaCl solution containing antibiotics (Pentabiótico; Fort Dodge, Campinas, Brazil). Cumulus-oocyte complexes (COCs) from follicles of

2–8 mm in diameter were aspirated using an 18-gauge needle attached to a 10 ml syringe. Only COCs with homogeneous cytoplasm surrounded by at least three layers of compact cumulus cells were selected for further IVM. After collection, the COCs were washed in manipulation medium composed of TCM-199 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 1% (v:v) antibiotic–antimycotic solution (Sigma-Aldrich), 0.1 mM sodium pyruvate (Sigma-Aldrich), 10% (v:v) fetal calf serum (FCS; Gibco, Grand Island, NY, USA) and 25 mM HEPES (Sigma-Aldrich). Groups of up to 50 COCs were placed in 500 μ l of maturation medium composed of TCM-199 containing 10% (v:v) FCS, 0.1 mM sodium pyruvate, 10 ng/ml epidermal growth factor (Sigma-Aldrich), 100 μ M cysteamine (Sigma-Aldrich), 20 μ g/ml FSH/LH (Pluset; Hertape Calier, Barcelona, Spain), 1 μ g/ml 17 β -estradiol (Sigma-Aldrich), 1% (v:v) antibiotic–antimycotic solution, and 1 mM L-glutamine (Sigma-Aldrich). IVM was performed at 38.5°C for 23–24 h in an humidified atmosphere of 5% CO₂.

In vitro fertilization (IVF)

Oocytes were submitted to IVF with frozen–thawed semen of a bull with proven fertility. The semen was thawed for 5 s in air and 25 s in a water bath at 37°C. The semen was separated in 4 ml of Percoll gradient (Sigma-Aldrich; 55%/90%) by centrifugation at 700 g for 25 min. The Percoll-separated semen was washed twice with 2 ml of BO medium added with 5 mM caffeine (Sigma-Aldrich) and 20 UI/ml heparin (Calbiochem, Merck, Darmstadt, Germany). After washing, the semen was diluted with BO added with 10 mg/ml bovine serum albumin (BSA; Sigma-Aldrich) to achieve a final concentration of 20 \times 10⁶ spermatozoa/ml. Finally, the COCs subjected to IVM were washed in manipulation medium and co-incubated with a suspension of semen in droplets of 100 μ l covered with mineral oil (Sigma-Aldrich) at 38.5°C in a humidified atmosphere of 5% CO₂. At 6 h post-IVF, presumptive zygotes were denuded by vortexing in manipulation medium and distributed randomly for respective groups of exposure or microinjection experiments.

Exposure to dLCr

Zygotes were exposed to dLCr for 6 h and after that they were transferred to droplets composed of 5 μ l of dLCr solution and 45 μ l of SOF^{-saa} and maintained at 38.5°C in an atmosphere of 5% CO₂, 5% O₂, 90% N₂. dLCr solution was prepared in NaCl 150 mM to achieve concentrations of 0 μ M (vehicle), 5 μ M (0.025 μ g/ μ l) and 50 μ M (0.0625 μ g/ μ l) in the culture medium. After exposure, the embryos were washed extensively in manipulation medium and subjected to embryo culture as described ahead. A group not exposed to dLCr (IVF group) was performed as the negative control. In addition, the exposure of zygotes to higher concentrations of dLCr: 25 μ M (0.125 μ g/ μ l) and 50 μ M (0.25 μ g/ μ l) was evaluated.

Experiment 3: Assess the efficiency of bovine embryo transfection with DNA–dLCr

Cytoplasmic microinjection of DNA–dLCr complex

To assess the ability of dLCr to improve exogenous DNA expression, DNA–dLCr complexes were first microinjected into the cytoplasm of IVF presumptive zygotes. The complex was prepared with pEGFP-N1, which encodes a red shifted variant of the wild type GFP reporter gene, and dLCr in 150 mM NaCl for at least 30 min. The DNA:peptide mass ratio for complex formation was

1:25 (as defined in experiment 1). Also, a positive control group was performed by microinjection of a solution composed of only pEGFP-N1 plasmid (25 ng/ μ l). Next, 5 μ l of solution were back-filled in microinjection capillaries (FemtoTip II; Eppendorf, Hamburg, Germany) with an internal tip diameter of approximately 0.5 μ m. Presumptive zygotes were transferred to 50 μ l droplets of manipulation medium in a 60 mm dish and covered with mineral oil. Zygotes were fixed by suction to a holding pipette, meanwhile the capillary was pushed through the embryo's zona pellucida and cytoplasm membrane. DNA–dLCr and DNA alone solutions were injected using a FemtoJet (Eppendorf) set as follows: injection pressure = 300 hPa, compensation pressure = 10 hPa, injection time = 0.5 s. Embryo micromanipulation was performed in a Narishige hydraulic micromanipulator (Narishige Science, Tokyo, Japan) mounted on a Nikon Eclipse TE2000 inverted microscope (Nikon, Tokyo, Japan). The microinjection procedure is described in Supporting Information. After injection, the zygotes were transferred into droplets of culture medium. In addition, an IVF control group (not microinjected) was performed.

Embryo culture and in vitro development assessment

Embryo culture was performed in 50 μ l droplets of SOF medium supplemented with 0.8% (w:v) BSA and 2.5% (v:v) FCS under mineral oil at 5% CO₂, 5% O₂, 90% N₂ and 38.5°C in high humidity. Embryo cleavage rate was assessed at day 2 post-IVF and blastocyst formation rates were evaluated at day 7 (D7) and day 8 (D8). At D8, hatching/hatched embryos were counted to assess embryo quality by means of hatching rate. GFP expression was evaluated under ultraviolet (UV) light using the Nikon Eclipse TE2000 microscope (excitation filter at 488 nm and emission filter at 530 nm) at day 5 (D5) and D7 of *in vitro* culture.

Data and statistical analysis

Statistical analyses were performed using Prism 6.0 software (GraphPad Software Inc., La Jolla, CA, USA). For stoichiometry assay, complexed DNA rate was assessed by one-way analysis of variance (ANOVA) multiple comparisons. In the kinetics assay, complexed DNA rate was evaluated by multiple *t*-test for differences between groups at the same time and by one-way ANOVA repeated measurements for differences between times at the same group. In complex stability assay, the complexed DNA rate was assessed by multiple *t*-test for differences between groups at the same time and by two-way ANOVA multiple comparisons for differences between times at the same group. The statistical analysis of cleavage, blastocyst, hatching and GFP expression rates was assessed using non-parametric Fisher's exact test. For all tests, a *P*-value < 0.05 was considered to be statistically significant.

Results

Experiment 1: Stoichiometry and kinetics of complex formation

Figure 1 shows that proportions of 1:100 and 1:50 DNA–dLCr reached higher (*P* < 0.05) complexation efficiency than DNA–Ncr 1:10 and lipofectamine. In addition, similar rates of complexed DNA (*P* > 0.05) were observed between those proportions, which were able to complex the maximal amount of DNA (over 90%) within 30 min of incubation. However, there was no difference when 1:25 DNA–dLCr and both controls (*P* > 0.05)




Figure 1. Stoichiometry of DNA-disulphide-less crotamine (dLCr) complex formation assessed by fluorophore exclusion assay. A DNA-dLCr complex was formed at 1:100, 1:50, 1:25, and 1:10 DNA:peptide mass ratios. Native crotamine (NCr) at 1:10 (DNA:peptide; wt:wt) and lipofectamine 2000 (Lipo) were used as positive controls. ^{a-c}Different lowercase letters indicate statistical differences ($P < 0.05$).




Figure 2. Kinetics of DNA-disulphide-less crotamine (dLCr) complex formation assessed by fluorophore exclusion assay. A DNA-dLCr complex was formed at 1:50, 1:25, and 1:10 (DNA:peptide; wt:wt). Complexed DNA was measured at 0, 5, 30, 60 and 90 min of complexation. Native crotamine (NCr) was used as a positive control at 1:10 DNA:peptide mass ratio. Different lowercase letters (a-d) indicate statistical differences between groups at different times and different uppercase letters (A-C) indicate statistical differences between times within the same group ($P < 0.05$).

were compared. Conversely, the proportion of 1:10 DNA-dLCr, resulted in the lowest ($P < 0.05$) complexation (less than 35%).

According to kinetics data, the DNA complexation by dLCr seems to occur very fast (Fig. 2). Therefore, for 1:50 or 1:25 DNA-dLCr more than 75% of the DNA was complexed by the peptide within 5 min of incubation. For all DNA-dLCr groups, the efficiency of the complexation was higher or similar than the 1:10 DNA-NCr group within 30 min of incubation. At 60 min incubation, the 1:50 DNA-dLCr group achieved a complexation rate of 99.6%, which was similar to 1:25 (95.8%) group, although higher ($P < 0.05$) than the 1:10 DNA-dLCr (63.0%) and




Figure 3. Stability of DNA-disulphide-less crotamine (dLCr) complex in embryo culture medium (SOF^{saa}) assessed by fluorophore exclusion assay. DNA-dLCr complex were formed at 1:25 DNA:peptide mass ratio for 30 min, diluted in SOF^{saa}, and then measured at 0, 180 and 360 min of incubation. Native crotamine (NCr) was used as positive control at 1:10 DNA:peptide mass ratio. There was no statistical difference between groups at diverse times and between times within the same group ($P > 0.05$).

1:10 DNA-NCr (76.1%) groups. The 1:10 dLCr group seems to have the slowest complexation, reaching less than 25% DNA complexation at 5 min and less than 65% at 60 min.

Experiment 1: Complex stability in embryo culture medium

To evaluate the stability of DNA-dLCr complexes in a DNA-free culture medium, complexes were incubated in SOF^{saa} medium and analyzed at 0, 180 and 360 min intervals (Fig. 3). No statistical difference was observed when comparing DNA-dLCr and DNA-NCr at the same time of incubation nor when comparing the different times within the same group ($P > 0.05$). Therefore, it was observed that there was no additional complexation or degradation of complexes previously formed in NaCl solution.

Experiment 2: In vitro development of embryos exposed to dLCr

In this experiment, the potential embryotoxicity of dLCr was assessed by evaluating the *in vitro* development of IVF bovine embryos exposed to dLCr for 6 h. The effects were recorded by means of embryo cleavage rate, blastocyst formation at D7 and D8 rates and hatching rate of groups exposed to 5 or 12.5 μM dLCr. One control group consisted of embryos exposed to SOF^{saa} medium with vehicle solution and without dLCr for 6 h (0 μM dLCr), and another consisted of embryos not exposed to vehicle solution and dLCr (IVF control). *In vitro* embryo development is shown in Table 1.

Cleavage, blastocyst productions and blastocyst hatching rates were similar among groups exposed to dLCr, 0 μM dLCr and IVF control ($P > 0.05$). In addition, higher dLCr concentrations (25 and 50 μM , i.e., 0.125 $\mu\text{g}/\mu\text{l}$ and 0.25 $\mu\text{g}/\mu\text{l}$, respectively, for 6 h) also did not affect the development of *in vitro* fertilized bovine embryos (Table 2). Therefore, exposure of zygotes for 6 h to up to 50 μM dLCr had no detrimental effect on *in vitro* embryo development.

Table 1. Effect of low concentrations of disulphide-less crotonamine (dLCr) on development of *in vitro* fertilized (IVF) bovine embryos

dLCr (μM)	Zygotes	Cleavage (%)	Blastocysts (%)		
			Day 7	Day 8	Hatching (%) [*]
12.5	161	129 (80.1) ^a	69 (42.9) ^a	71 (44.1) ^a	18 (25.4) ^a
5	162	126 (77.8) ^a	60 (37.0) ^a	62 (38.3) ^a	15 (24.2) ^a
0 (vehicle)	119	87 (73.1) ^a	50 (42.0) ^a	49 (41.2) ^a	13 (26.5) ^a
IVF control	118	93 (78.8) ^a	54 (45.8) ^a	51 (43.2) ^a	8 (15.7) ^a

Experiment was replicated four times.

^aSimilar superscripts within the same column mean statistical similarity ($P < 0.05$).

^{*}Calculated from total number of blastocysts at day 8.

Table 2. Effect of high concentrations of disulphide-less crotonamine (dLCr) on development of *in vitro* fertilized (IVF) bovine embryos

dLCr (μM)	Zygotes	Cleavage (%)	Blastocyst (%)		Hatching (%) [*]
			Day 7	Day 8	
50	171	107 (62.6) ^a	46 (26.9) ^a	43 (25.1) ^a	15 (34.9) ^{a,b}
25	170	113 (66.5) ^a	51 (30.0) ^a	52 (30.6) ^a	19 (36.5) ^a
0 (vehicle)	120	75 (62.5) ^a	30 (25.0) ^a	32 (26.7) ^a	15 (46.9) ^a
IVF control	120	83 (69.2) ^a	42 (35.0) ^a	42 (35.0) ^a	7 (16.7) ^b

Experiment was replicated four times.

^{a,b}Different superscripts within the same column differ significantly ($P < 0.05$).

^{*}Calculated from total number of blastocysts.

Experiment 3: Transfection of embryos by microinjection of DNA-dLCr complex

Microinjection of the 1:25 DNA-dLCr complex was compared with microinjection of DNA alone by means of *in vitro* development and emission of GFP fluorescence. Also, an IVF control group was performed to assess the viability of *in vitro* embryo culture (Table 3). For embryo cleavage and blastocyst production (D7 and D8), microinjected groups had lower rates ($P < 0.05$) than the IVF control. Nevertheless, embryo development parameters were similar ($P > 0.05$) among groups of embryos microinjected (DNA-dLCr and DNA alone). To determine the quality of blastocysts formed, hatching rate was evaluated for all groups and no difference ($P > 0.05$) was found among these (Table 3).

The rate of GFP expression is shown in Table 3. In total, 4.6% and 2.8% of cleaved embryos was observed to express fluorescence at D5 and D7, respectively, after microinjection of plasmid alone. Use of the DNA-dLCr complex for microinjection did not increase the number of GFP-positive embryos when compared with plasmid DNA alone ($P > 0.05$). Additionally, there was no detectable qualitative transgene expression on embryos microinjected with DNA-dLCr complex in comparison with microinjection of DNA plasmid alone.

Discussion

To date, this is the first study to describe the use of a synthetic version of disulphide-less (linear) crotonamine for DNA complex formation and gene transfer. The native peptide is rich in positive amino acid residues (nine lysine and two arginine residues) and six cysteine. The positive residues conferred a net positive charge to

this molecule, i.e. a basic characteristic and cysteine make up three precisely arranged disulphide bonds (Nicastro *et al.*, 2003; Fadel *et al.*, 2005). In addition, the presence of two histidine residues could provide an extra positive charge to these molecules in physiological pH and, especially, in the pH of the medium (Marinovic *et al.*, 2016).

In the present study, the ability of a new synthetic disulphide-less crotonamine, i.e. the linear version free of the three S-S bonds, was evaluated for its ability to form a complex with DNA molecules. It is known that crotonamine binding to nucleic acids seems to rely on electrostatic interaction; nucleic acids have a net negative charge while crotonamine possesses an overall positive surface. One region, in particular, was suggested due to being potentially involved in the interaction with DNA. The region is comprised of the sequence RWRWK (Arg-Trp-Arg-Trp-Lys) and corresponds to residues 31–35 of NCr (Chen *et al.*, 2012). In the linear disulphide-less peptide, this sequence was not altered, therefore preserving the ability of dLCr to bind to DNA. The rationale to use disulphide-less crotonamine as the delivery tool for embryo transfection instead of the native disulphide-bond folded crotonamine relied on the fact that CPPs should make a complexation between the peptide and DNA complex that was strong enough to permit stable uptake through the zona pellucida and/or cell membrane translocation, but should be sufficiently weak to permit the release of DNA though dissociation into the cell cytoplasm to enable it to traffic to the nucleus. In our previous studies (Campelo *et al.*, 2016a, 2016b), bovine embryos were used as a model for gene transfer with DNA-NCr complexes. However, the use of the DNA-NCr complex did not improve the transgene expression rate, supposedly because of strong DNA-peptide binding within embryo cells (Campelo *et al.*, 2016b). Therefore, it was desirable to evaluate whether modified crotonamine peptides, such as dLCr could reduce the binding strength of DNA-peptide and circumvent such physicochemical behaviour.

In fact, it was observed here that the capacity of complexation with DNA of dLCr was reduced when compared with NCr. In experiment 1, stoichiometry of DNA-dLCr and DNA-NCr complexes at the same proportion (1:10) was analyzed and complexed DNA was significantly reduced (34.9% vs 68.1%). The DNA-dLCr complex achieved similar complexation for 1:10 DNA-NCr (81.0% vs 68.1%) only at the 1:25 proportion, i.e. using approximately 2.5 times higher dLCr than NCr peptide mass for the same mass of plasmid DNA. It was expected that changes in the primary sequence, by substitution of cysteine residues in crotonamine with 2-aminobutyric acid residues (Abu), would not alter membrane translocation, but facilitate peptide:DNA dissociation and preserve the accumulation patterns in cell cytoplasm.

Nevertheless, linear peptides usually have lower stability due to higher liability to proteases when compared with more compact disulphide-bond-stabilized structures, as for native crotonamine (Marinovic *et al.*, 2016). Despite this concern, it was verified that the DNA-dLCr complex was highly stable in embryo culture medium and any degradation in peptide-DNA was observed even after incubation for 6 h (61.3% at 360 min vs 60.5% at 0 min). The stability of a given CPP in complete culture medium and in the presence of serum is a highly useful property in gene delivery (Rádis-Baptista *et al.*, 2017). Here, the potential toxic effect of dLCr on IVF bovine embryos was also evaluated and a significantly higher concentration of dLCr (12.5 μM) did not cause any deleterious effect upon IVF embryo development. Even at higher concentrations of dLCr (25 and 50 μM), toxicity in post-IVF early bovine embryos was undetectable. NCr has been extensively tested

Table 3. Embryo development and enhanced green fluorescent protein (EGFP) expression of microinjected *in vitro* fertilized (IVF) bovine embryos with DNA-disulphide-less crotonamine (DLCr) complex (+) or plasmid DNA alone (–)

Treatment	dLCr	Zygotes	Cleavage (%)	Blastocysts (%) [*]			Number of embryos expressing EGFP (%) ^{***}	
				Day 7	Day 8	Hatching (%) ^{**}	Day 5	Day 7
Intracytoplasmic microinjection	+	189	101 (53.4) ^a	32 (16.9) ^a	33 (17.5) ^a	7 (21.2) ^a	0 (0.0) ^a	0 (0.0) ^a
	–	191	108 (56.5) ^a	33 (17.3) ^a	32 (16.8) ^a	8 (25.0) ^a	5 (4.6) ^a	3 (2.8) ^a
IVF control	NA	210	182 (86.7) ^b	85 (40.5) ^b	84 (40.0) ^b	9 (10.7) ^a	NA	NA

Experiment was replicated five times.

NA, not applicable.

^{*}Rates calculated over zygotes.

^{**}Rates calculated from total number of blastocysts at day 8.

^{***}Rates calculated over cleaved embryos.

^{a,b}Different superscripts within the same column differ significantly ($P < 0.05$).

on eukaryotic cells such as mouse embryonic stem cells, human carcinoma HCT116 cells and CHO-K1 cells (Rádis-Baptista and Kerkis, 2011). Specifically, mammalian embryos were also used as model to detect possible toxic effects of crotonamine. However, for murine and bovine species (Kerkis *et al.*, 2004; Campelo *et al.*, 2016a) no embryotoxicity was noticed when using native crotonamine ranging from 1 μM to 10 μM , for up to 24 h. Overall, in agreement with these data and reports, native and linear crotonamine are harmless to embryo cells in micromolar concentrations ($< 50 \mu\text{M}$ for bovine and $< 10 \mu\text{M}$ for mice).

Cytoplasmic microinjection of plasmids in zygotes is a simple alternative to drive ectopic expression of exogenous DNA in embryos (Iqbal *et al.*, 2009). The development of a simple and effective method that could allow the delivery of exogenous DNA into the zygote's cell membrane, through the zona pellucida, would be a great advantage to transgenic technologies, especially to the recent introduced engineered site-directed nucleases (ESDNs) methodologies, such as the CRISPR/Cas9 system (Kim, 2016). These new technologies may require the injection of high concentrations of the transgene construct. In this scenario, improvements, such as using DNA construction in association with substances that enable further increase in efficiency of cytoplasmic microinjection, are a great advantage. For example, injection of DNA-liposome lipoplexes into IVF zygotes increased the rate of GFP+ blastocysts to 12% in cattle (Vichera *et al.*, 2011). In accordance, here it was evaluated if enhancement in efficiency of cytoplasmic microinjection of DNA carrying a GFP reporter could be achieved by associating exogenous DNA with dLCr by a non-covalent interaction. *In vitro* development parameters and fluorescence for GFP of IVF bovine embryos was compared with microinjection of DNA alone and IVF control groups.

Cleavage and blastocyst production at D7 and D8 were lower in the microinjected group than in the IVF control group, demonstrating, as expected, a possible negative effect of microinjection upon embryo development. Nevertheless, embryo development parameters were similar between embryos microinjected with DNA-dLCr or with DNA alone. Therefore, no detrimental effect was detected by using dLCr complexed with DNA for microinjection of post-IVF bovine embryos. A study using the same GFP plasmid construct with a microinjection semi-automated system was carried out to determine the most appropriate microinjection time, concentration and volume in IVF and parthenogenetic pig embryos. In this study, microinjection also reduced the developmental competence of injected zygotes, even when using the best conditions defined by the study (Malaweera *et al.*, 2014).

In contrast, a study in buffalo using an ApaI I linearized pEGFP-N1 plasmid, but with a manual microinjection system, resulted in cleavage and blastocyst development rates similar to those of non-injected IVF embryos (Meng *et al.*, 2015).

Concerning the expression of GFP, a low rate was achieved (4.6% at D5 and 2.8% at D7) for group of embryos microinjected with plasmid DNA alone. This reduced rate could be explained by the low chance and the efficiency by which embryos normally express an exogenous cassette. In a correlated work, no GFP-expressing IVF bovine embryos were obtained after sperm-mediated gene transfer treatment, when exogenous DNA quantification could be assessed by real-time PCR (Campos *et al.*, 2011). As in our study, this group used a pEGFP-N1 plasmid containing the CMV promoter. Previously, the CMV promoter was thought to present low efficiency (Rieth *et al.*, 2000) and, in this case, an additional CMV enhancer would be necessary to improve GFP expression. Moreover, injected DNA should be able to traffic to the nucleus and to be expressed even if DNA is integrated into the genome, randomly, and in a non-active transcription region of the chromosome (Hacker and Balasubramanian, 2016). This event is a significant drawback for genetic engineering regarding stable insertion of exogenous DNA in the genomes of farm animals, and an essential step for production of transgenic animal (Garrels *et al.*, 2012) that could be better achieved by CRISPR/Cas 9 technology.

When comparing embryos microinjected with plasmid alone or with the DNA-dLCr complex, the rate of DNA expression of exogenous DNA in bovine embryos was not comparatively improved. The high affinity for DNA and binding capacity of dLCr might again restrain the release of the GFP plasmid gene in the complex for protein expression, similar to found previously when using native crotonamine to induce exogenous DNA expression in bovine embryos (Campelo *et al.*, 2016b). Therefore, it was hypothesized that dLCr remains complexed to exogenous DNA even inside the cytoplasm of embryo cells, and this possibly led to very low GFP expression and detectable fluorescence.

The results indicated that dLCr effectively formed a complex with DNA in a concentration- and time-dependent manner. Its application in embryo culture medium is possible for concentrations up to 50 μM for 6 h. However, transgene expression was not comparatively improved using dLCr complexed with a GFP reporter plasmid DNA. In conclusion, dLCr formed a stable complex with DNA, in the presence of complete embryo medium and was not embryotoxic. Substitution of the reporter gene will be under consideration for further utilization of dLCr as a tool to carry genes intracellularly and to improve heterologous gene expression.

Additionally, the dLCr peptide sequence should be redesigned to improve GFP expression.

Acknowledgements. The authors are thankful to Dr Eduardo B. Oliveira (University of São Paulo, Ribeirão Preto, Brazil) for supplying native crotamine.

Financial support. This work was supported by the following Brazilian funding agencies: the Cearense Foundation for Scientific and Technological Development Support (FUNCAP, Pronex Programme), the National Council for Scientific and Technological Development (CNPq) and the Coordination for the Improvement of Higher Level or Education-Personnel (CAPES, Toxinology Programme).

Conflicts of interest. The authors have no conflicts of interest to declare.

Ethical standards. All animal experiments in this study were approved by the Ethics Committee on Animal Use of State University of Ceará (1672976/2017).

Supporting information. Supporting information of an MP4 video file is available for this paper.

Supplementary material. To view supplementary material for this article, please visit <https://doi.org/10.1017/S0967199419000716>

References

- Campelo IS, Pereira AF, Alcântara-Neto AS, Canel NG, Souza-Fabjan JMG, Teixeira DIA, Camargo LS, Melo LM, Rádis-Baptista G, Salamone DF and Freitas VJF (2016a) Effect of crotamine, a cell-penetrating peptide, on blastocyst production and gene expression of *in vitro* fertilized bovine embryos. *Zygote* **24**, 48–57.
- Campelo IS, Canel NG, Bevacqua RJ, Melo LM, Rádis-Baptista G, Freitas VJF and Salamone DF (2016b) Crotamine, a cell-penetrating peptide, is able to translocate parthenogenetic and *in vitro* fertilized bovine embryos but does not improve exogenous DNA expression. *J Assist Reprod Genet* **33**, 1405–13.
- Campos VF, de Leon PM, Komninou ER, Dellagostin OA, Deschamps JC, Seixas FK and Collares T (2011) NanoSMGT: transgene transmission into bovine embryos using halloysite clay nanotubes or nanopolymer to improve transfection efficiency. *Theriogenology* **76**, 1552–60.
- Carballada R, Relloso M and Esponda P (2002) Generation of transgenic mice by transfection of pronuclear embryos using lipid–DNA complexes. *Zygote* **10**, 209–16.
- Chang K, Qian J, Jiang M, Liu YH, Wu MC, Chen CD, Lai CK, Lo HL, Hsiao CT, Brown L, Bolen J Jr, Huang HI, Ho PY, Shih PY, Yao CW, Lin WJ, Chen CH, Wu FY, Lin YJ, Xu J and Wang K (2002) Effective generation of transgenic pigs and mice by linker based sperm-mediated gene transfer. *BMC Biotechnol* **2**, 5.
- Chen PC, Hayashi MAF, Oliveira EB and Karpel RL (2012) DNA-interactive properties of crotamine, a cell-penetrating polypeptide and a potential drug carrier. *PLoS One* **7**, e48913.
- Ebert KM, Selgrath JP, DiTullio P, Denman J, Smith TE, Memon MA, Schindler JE, Monastersky GM, Vitale JA and Gordon K (1991) Transgenic production of a variant of human tissue-type plasminogen activator in goat milk: generation of transgenic goats and analysis of expression. *Biotechnology* **9**, 835–8.
- Fadel V, Bettendorff P, Herrmann T, de Azevedo WF Jr, Oliveira EB, Yamane T and Wüthrich K (2005) Automated NMR structure determination and disulfide bond identification of the myotoxin crotamine from *Crotalus durissus terrificus*. *Toxicon* **46**, 759–767.
- Freitas VJF, Alcântara-Neto AS, Pereira AF, Campelo IS, Melo LM and Rádis-Baptista G (2014) Assessing the complex formation between crotamine – a natural cell penetrating peptide – and DNA using high sensitive fluorescence exclusion assay. *Clon Transgen* **3**, 128.
- Garrels W, Ivics Z and Kues WA (2012) Precision genetic engineering in large mammals. *Trends Biotechnol* **30**, 386–93.
- Gonçalves JM and Polson A (1947) The electrophoretic analysis of snake venoms. *Arch Biochem* **13**, 253–9.
- Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA and Ruddle FH (1980) Genetic transformation of mouse embryos by microinjection of purified DNA. *Proc Natl Acad Sci USA* **77**, 7380–4.
- Hacker DL and Balasubramanian S (2016) Recombinant protein production from stable mammalian cell lines and pools. *Curr Opin Struct Biol* **38**, 129–36.
- Hammer RE and Pursel VG (1985) Production of transgenic rabbits, sheep and pigs by microinjection. *Nature* **315**, 680–3.
- Iqbal K, Barg-Kues B, Brol S, Bode J, Niemann H and Kues WA (2009) Cytoplasmic injection of circular plasmids allows targeted expression in mammalian embryos. *Biotechniques* **47**, 959–68.
- Jaenisch R and Mintz B (1974) Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. *Proc Natl Acad Sci USA* **71**, 1250–4.
- Kerkis A, Kerkis I, Rádis-Baptista G, Oliveira EB, Vianna-Morgante AM, Pereira LV and Yamane T (2004) Crotamine is a novel cell-penetrating protein from the venom of rattlesnake *Crotalus durissus terrificus*. *FASEB J* **18**, 1407–9.
- Kim JS (2016) Genome editing comes of age. *Nat Protoc* **11**, 1573–8.
- Krimpenfort P, Rademakers A, Eyestone W, van der Schans A, van den Broek S, Kooiman P, Kootwijk E, Platenburg G, Pieper F, Strijker R and de Boer H (1991) Generation of transgenic dairy cattle using *in vitro* embryo production. *Biotechnology* **9**, 844–7.
- Kues WA and Niemann H (2011) Advances in farm animal transgenesis. *Prev Vet Med* **102**, 146–56.
- Li R, Miao J, Fan Z, Song S, Kong IK, Wang Y and Wang Z (2018) Production of genetically engineered golden Syrian hamsters by pronuclear injection of the CRISPR/Cas9 complex. *J Vis Exp* **131**, 56263.
- Malaweera DBO, Ramachandra S, Wu JB, Oh SK, Kim SH, Kim SJ, Jang G and Cho JK (2014) Establishment of efficient microinjection system in the porcine embryos. *J Emb Transf* **29**, 59–66.
- Marinovic MP, Dal Mas C, Monte GG, Felix D, Campeiro JD and Hayashi MAF (2016) Crotamine: function diversity and potential applications. In P Gopalakrishnakone, H Inagaki, A Mukherjee, T Rahmy and CW Vogel (eds) *Snake venoms*. Dordrecht: Springer.
- Meng F, Li H, Wang X, Qin G, Oback B and Shi D (2015) Optimized production of transgenic buffalo embryos and offspring by cytoplasmic zygote injection. *J Anim Sci Biotechnol* **6**, 44.
- Nascimento FD, Hayashi MA, Kerkis A, Oliveira V, Oliveira EB, Rádis-Baptista G, Nader HB, Yamane T, Tersariol IL and Kerkis I (2007) Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans. *J Biol Chem* **282**, 21349–60.
- Nicastro G, Franzoni L, de Chiara C, Mancin AC, Giglio JR and Spisni A (2003) Solution structure of crotamine, a Na⁺ channel affecting toxin from *Crotalus durissus terrificus* venom. *Eur J Biochem* **270**, 1969–79.
- Pooga M and Langel Ü (2015) Classes of cell-penetrating peptides. *Methods Mol Biol* **1324**, 3–28.
- Rádis-Baptista G and Kerkis I (2011) Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties. *Curr Pharm Des* **17**, 4351–61.
- Rádis-Baptista G, de la Torre BG and Andreu D (2008) A novel cell-penetrating peptide sequence derived by structural minimization of a snake toxin exhibits preferential nucleolar localization. *J Med Chem* **51**, 7041–4.
- Rádis-Baptista G, de la Torre BG and Andreu D (2012) Insights into the uptake mechanism of NrTP, a cell-penetrating peptide preferentially targeting the nucleolus of tumour cells. *Chem Biol Drug Des* **79**, 907–15.
- Rádis-Baptista G, Campelo IS, Morlighem JRL, Melo LM and Freitas VJF (2017) Cell-penetrating peptides (CPPs): from delivery of nucleic acids and antigens to transduction of engineered nucleases for application in transgenesis. *J Biotechnol* **252**, 15–26.
- Rieth A, Pothier F and Sirard MA (2000) Electroporation of bovine spermatozoa to carry DNA containing highly repetitive sequences into oocytes and detection of homologous recombination events. *Mol Reprod Dev* **57**, 338–45.

- Salamone D, Baraño L, Santos C, Busmann L, Artuso J, Werning C, Prynck A, Carbonetto C, Dabsys S, Munar C, Salaberry R, Berra G, Berra I, Fernández N, Papouchado M, Foti M, Judewicz N, Mujica I, Muñoz L, Alvarez SF, González E, Zimmermann J, Criscuolo M and Melo C** (2006) High level expression of bioactive recombinant human growth hormone in the milk of a cloned transgenic cow. *J Biotechnol* **124**, 469–72.
- Stewart KM, Horton KL and Kelley SO** (2008) Cell-penetrating peptides as delivery vehicles for biology and medicine. *Org Biomol Chem*, **6**, 2242–55.
- Vichera G, Moro L and Salamone D** (2011) Efficient transgene expression in IVF and parthenogenetic bovine embryos by intracytoplasmic injection of DNA-liposome complexes. *Reprod Domest Anim* **46**, 214–20.
- Xu YN, Uhm SJ, Koo BC, Kwon MS, Roh JY, Yang JS, Choi HY, Heo YT, Cui XS, Yoon JH, Ko DH, Kim T and Kim NH** (2013) Production of transgenic Korean native cattle expressing enhanced green fluorescent protein using a FIV-based lentiviral vector injected into MII oocytes. *J Genet Genomics* **40**, 37–43.